

MAY 21 2001

Approved for use through 10/31/2002 OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	09/734,613
Filing Date	December 13, 2000
First Named Inventor	BRUGGEMANN; Marianne
Group Art Unit	1651
Examiner Name	Not Yet Assigned
Attorney Docket Number	37945-0009

(use as many sheets as necessary)

Sheet	1	of	7
-------	---	----	---

[illegible][illegible]

Date Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box

MAY 21 2001

PATENT & TRADEMARK OFFICE

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2



of

7


Complete if Known

Application Number	09/734,613
Filing Date	December 13, 2000
First Named Inventor	BRUGGEMANN, Marianne
Group Art Unit	1651
Examiner Name	Not Yet Assigned
Attorney Docket Number	37945-0009

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials ²	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A05	POPOV, A. et al; "Assembly and Extension of Yeast Artificial Chromosomes to Build a Large Locus"; Gene: An International Journal on Genes and Genomes; October 24, 1998; pages 195-201; Vol. 177, No. 1; Elsevier Science Publishers, Great Britain	
	A06	GORMAN, J. et al; "The Igk 3' Enhancer Influences the Ratio of Igk Versus Igλ B Lymphocytes"; Immunity; September 1998; pages 241-252; Vol. 5, No. 3; Cell Press	
	A07	POPOV, A. et al; "A Human Immunoglobulin λ Locus Is Similarly Well Expressed in Mice and Humans"; J. Exp. Med; May 17, 1998; pages 1811-1820; Vol. 189, No. 10; The Rockefeller University Press	
	A08	HOOD, L. et al; "Light Chain Evolution"; Cold Spring Harbour Symp. Quant. Biol.; 1967; pages 133-146; Vol. 32	
	A09	McINTIRE, K.R. et al; "Mouse Immunoglobulin Light Chains: Alteration of κ:λ Ratio"; Federal Proc.; March/April 1970; page 704; Vol. 29; No. 2; Federation of American Societies for Experimental Biology	
	A10	ARUN, S.S. et al; "Immunohistochemical Examination of Light-Chain Expression (λ/κ Ratio) in Canine, Feline, equine, Bovine and Porcine Plasma Cells"; J. Vet. Med.; February 1998; pages 573-578; Vol. 43; Blackwell Wissenschafts-Verlag; Berlin, Germany	
	A11	HIETER, P. "Human Immunoglobulin κ Light-Chain Genes are Deleted or Rearranged in λ-Producing B Cells"; Nature; April 2, 1981; pages 368-372; Vol. 290; Macmillan Journals Ltd.	
	A12	COLECLOUGH, C. et al; "Aberrant Rearrangements Contribute Significantly to the Allelic Exclusion of Immunoglobulin Gene Expression"; Nature; April 2, 1981; pages 372-378; Vol. 290; Macmillan Journals Ltd.	
	A13	SELSING, E. et al; "Immunoglobulin λ genes"; Immunoglobulin Genes Second Edition; pages 193-203; Academic Press; London, England	
	A14	BERG, J. et al; "Immunoglobulin λ Gene Rearrangement Can Precede κ Gene Rearrangement"; Developmental Immunology; 1990; Pages 53-57; Vol. 1; Harwood Academic Publishers GmbH; Great Britain	
	A15	ABKEN, H. et al; "Re-organization of the Immunoglobulin Kappa Gene on Both Alleles is not an Obligatory Prerequisite for Ig Lambda Gene Expression in Human Cells"; Immunology; August 12, 1991; pages 709-713; Vol. 74	

Examiner
Signature



Date

Considered

8/2/05

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

MAY 21 2001

PATENT & TRADEMARK OFFICE

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

7

Complete if Known

Application Number	09/734,613
Filing Date	December 13, 2000
First Named Inventor	BRUGGEMANN, Marianne
Group Art Unit	1651
Examiner Name	Not Yet Assigned
Attorney Docket Number	37945-0009

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A16	✓ TAKEMORI, T. et al; "Lambda Chain Expression at Different Stages of Ontogeny in C57BL/6, BALB/c and SJL Mice"; Eur. J Immunology; 1981; pages 618-625; Vol. 11; Verlag Chemie GmbH, Weinheim, Germany	
	A17	✓ McGUIRE, K. et al; "κ/λ Shifts Do Not Occur During Maturation of Murine B Cells"; The Journal of Immunology; October 4, 1981; pages 1670-1673; Vol. 127, No. 4; The American Association of Immunologists; United States	
	A18	✓ KESSLER, S. et al; "Surface Membrane κ and λ Light Chain expression on Spleen Cells of Neonatal and Maturing Normal and Immune-Defective CBA/n Mice: The κ/λ Ratio is Constant"; The Journal of Immunology; October 4, 1981; pages 1674-1678; Vol. 127, No. 4; The American Association of Immunologists; United States	
	A19	✓ LeJEUNE, J.M. et al; "Estimate of the Light Chain Repertoire Size of Fetal and Adult BALB/cJ and CBA/J Mice"; The Journal of Immunology; August 2, 1982; pages 673-677; Vol. 129, No. 2; The American Association of Immunologists; United States	
	A20	✓ ROLINK, A. et al; "The κ/λ Ratio in Surface Immunoglobulin Molecules on B Lymphocytes Differentiating from D _H J _H Rearranged Murine pre-B Cell Clones <i>in vitro</i> "; Eur. J. Immunol. 1991; pages 2895-2898; Vol. 21; Verlagsgesellschaft mbH; Weinheim, Germany	
	A21	✓ OSMOND, D. et al; "Murine B Lymphopoiesis: Towards a Unified Model"; Immunology Today; February 1998; pages 65-68; Vol. 19, No. 2; Elsevier Science Ltd.; Great Britain	
	A22	✓ ZOU et al; "Gene Targeting in the Igκ Locus: Efficient Generation of λ Chain-Expressing B Cells, Independent of Gene Rearrangements in Igκ"; The EMBO Journal, 1993; pages 811-820; Vol. 12, No. 3; Oxford University Press	
	A23	✓ ARAKAWA, H. et al; "ReEvaluation of the Probabilities for Productive Rearrangements on the κ and λ Loci"; International Immunology, 1996; pages 91-99; Vol. 8, No. 1; Oxford University Press	
	A24	✓ GLOZAK, M. et al; "The Human λ Immunoglobulin Enhancer is Controlled by Both Positive Elements and Developmentally Regulated Negative Elements"; Molecular Immunology; 1996; pages 427-438; Vol. 33, No. 4/5; Elsevier Science Ltd.; Great Britain	
	A25	✓ ASENBAUER, H. et al; "Tissue-Specific Deoxyribonuclease I-Hypersensitive Sites in the Vicinity of the Immunoglobulin C _κ Cluster of Man"; Eur. J. Immunol. 1996; pages 142-150; Vol. 26; Verlagsgesellschaft mbH; Weinheim, Germany	
	A26	✓ GORMAN, J. et al; "The Igκ 3' Enhancer Influences the Ratio of Igκ Versus Igλ B Lymphocytes"; Immunity; September 1996; pages 241-252; Vol. 5; Cell Press	

Examiner
Signature

[Handwritten Signature]

Date
Considered

4/2/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1448A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/734,613		
		Filing Date	December 13, 2000		
		First Named Inventor	BRUGGEMANN, Marianne		
		Group Art Unit	1651		
		Examiner Name	Not Yet Assigned		
Sheet	4	of	7	Attorney Docket Number	37945-0009

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A27	FRIPPIAT, J.-P. et al; "Organization of the Human Immunoglobulin Lambda Light-Chain Locus on Chromosome 22q11.2"; Human Molecular Genetics; 1995; pages 983-991; Vol. 4; No. 6; Oxford University Press	
	A28	KAWASAKI, K. et al; "One-Megabase Sequence Analysis of the Human Immunoglobulin λ Gene Locus"; Genome Research; 1997; pages 250-261; Vol. 7; Cold Spring Harbor Laboratory Press; New York, United States	
	A29	GIUDICELLI, V. et al; "IMGT, The International ImMunoGeneTics Database"; Nucleic Acids Research; 1997; pages 208-211; Vol. 25; No. 1; Oxford University Press	
	A30	IGNATOVICH, O. et al; "The Creation of Diversity in the Human Immunoglobulin V _λ Repertoire"; Journal Molecular Biology; 1997; pages 69-77; Vol. 268; Academic Press Limited	
	A31	COMBRIATO, G. et al; "V _λ and J _λ -C _λ gene segments of the human immunoglobulin λ light chain locus are separated by 14 kb and rearrange by a deletion mechanism"; Eur. J. Immunol.; 1991; pages 1513-1522; Vol. 21; Verlagsgesellschaft mbH; Weinheim; Germany	
	A32	FOSTER, S. et al; "Molecular Mechanisms and Selective Influences that Shape the Kappa Gene Repertoire of IgM ⁺ B Cells"; J. Clinical Investigation; April 7, 1997; pages 1614-1627; Vol. 99; No. 7; The American Society of Clinical Investigation, Inc.	
	A33	IGNATOVICH, O; "The Creation of Diversity in the Human Immunoglobulin V1 Repertoire" Phd. Thesis; University of Cambridge; 1998	
	A34	BRIDGES, S.L., et al; "Somatic Mutation and CDR3 Lengths of Immunoglobulin κ Light Chains Expressed in Patients with Rheumatoid Arthritis and in Normal Individuals"; The Journal of Clinical Investigation, Inc.; August 1995; pages 831-841; Vol. 96; The American Society of Clinical Investigation, Inc.	
	A35	VICTOR, K. et al; "Limited Junctional Diversity in κ Light Chains"; Journal of Immunology; 1994; pages 3467 - 3475; Vol 152; The American Association of Immunologists	
	A36	DAVIES, N. et al; "Human Antibody Repertoires in Transgenic Mice: Manipulation and Transfer of YACs"; Antibody Engineering: A Practical Approach; 1996; pages 1-35; Department of Development and Signalling; Babraham Institute; Babraham, Cambridge; United Kingdom -	
	A37	HOGAN, B. et al; "Manipulating the Mouse Embryo: A Laboratory Manual"; 1994; Cold Spring Harbor Laboratory Press; United States of America	

Examiner Signature		Date Considered	8/2/05
--------------------	--	-----------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

MAY 21 2001

MAY 21 2001

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 7

Complete if Known

Application Number	09/734,613
Filing Date	December 13, 2000
First Named Inventor	BRUGGEMANN, Marianne
Group Art Unit	1651
Examiner Name	Not Yet Assigned
Attorney Docket Number	37945-0009

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
W	A38	ZOU, X. et al; "Subtle Differences in Antibody Responses and Hypermutation of λ Light Chains in Mice with a Disrupted κ Constant Region"; Eur. J. Immunology; 1995; pages 2154-2162; Vol.25; Verlagsgesellschaft mbH; Weinheim; Germany	
	A39	WURST, W. et al; "Production of Targeted Embryonic Stem Cell Clones"; Gene Targeting: A Practical Approach; 1993; pages 33-61; IRL Press; Oxford	
	A40	HERMANN, B. et al; "A Large Inverted Duplication Allows Homologous Recombination Between Chromosomes Heterozygous for the Proximal t Complex Inversion"; Cell; 1987; pages 813-825; Vol. 48	
	A41	GALFRÉ, G. et al; "Preparation of Monoclonal Antibodies: Strategies and Procedures"; Methods in Enzymology; 1981; pages 3-48; Vol. 73; Academic Press, Inc.	
	A42	TJUSSEN, P. et al; "Practice and Theory of Enzyme Immunoassays"; Laboratory Techniques in Biochemistry and Molecular Biology; 1985; Vol. 15. Burdon, R.H. and Knippenberg, P.H. (eds); Elsevier; Amsterdam, The Netherlands	
	A43	CHOMCZYNSKI, P. et al; "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction"; Analytical Biochemistry; April 1987; pages 156-159; Vol. 162; No. 1; The Academic Press, Inc. New York, United States	
	A44	FROHMAN, M. et al; "Rapid Production of Full-Length cDNAs from Rare Transcripts: Amplification Using a Single Gene-Specific Oligonucleotide Primer"; Proc. Natl. Acad. Sci.; December 1988; pages 8998 - 9002; Vol. 85	
	A45	AUSUBEL, F.M. et al; "Current Protocols in Molecular Biology"; 1995; Vol. 1 Wiley & Sons, United States	
	A46	WILLIAMS, S. et al; "Sequence and Evolution of the Human Germline V _H Repertoire"; J. Mol. Biol.; 1996; pages 220 -232; Vol. 284; Academic Press Limited	
	A47	CHEN, J. et al; "B Cell Development in Mice that Lack One or Both Immunoglobulin κ Light Chain Genes"; The EMBO Journal; 1997; pages 821-830; Vol. 12, No. 3; Oxford University Press; United Kingdom	
	A48	BRÜGGEMANN, M. et al; "Strategies for Expressing Human Antibody Repertoires in Transgenic Mice"; Immunology Today; August 1996; pages 391-397; Vol. 17; Elsevier Sciences Ltd.	

Examiner
Signature

Date
Considered


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

MAY 21 2001



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 7

Complete if Known

Application Number	09/734,613
Filing Date	December 13, 2000
First Named Inventor	BRUGGEMANN, Marianne
Group Art Unit	1651
Examiner Name	Not Yet Assigned
Attorney Docket Number	37945-0009

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A49	GREEN, L. et al; "Regulation of B Cell Development by Variable Gene Complexity in Mice Reconstituted with Human Immunoglobulin Yeast Artificial Chromosomes"; J. Exp. Med.; August 3, 1998; pages 483-495; Vol. 188; No. 3; The Rockefeller University Press	
	A50	ZOU, X. et al; "Dominant Expression of a 1.3 Mb human Igk Locus Replacing Mouse Light Chain Production"; The FASEB Journal; August 1998; pages: 1227-1232; Vol. 10	
	A51	XIAN, J. et al; "Comparison of the Performance of a Plasmid-Based Human Igk Minilocus and Yac-Based Human Igk Transloci for the Production of Human Antibody Repertoires in Transgenic Mice"; Transgenic; 1998; pages 333-343; Vol. 2; OPA; Malaysia	
	A52	GONZALEZ-FERNANDEZ, A. et al; "Somatic Mutation of Immunoglobulin λ Chains: A Segment of the Major Intron Hypermutates as Much as the Complementarity - Determining Regions"; Proc. Natl. Acad. Sci.; December 1994; pages 12614-12618; Vol. 91;	
	A53	LI, Y.S. et al; "The Regulated Expression of B Lineage Associated Genes During B Cell Differentiation in Bone Marrow and Fetal Liver"; J. Exp. Med; September 1993; pages 951-960; Vol 178; The Rockefeller University Press	
	A54	HARDY, R. et al; "Resolution and Characterization of Pro-B and Pre-Pro-B Cell Stages in Normal Mouse Bone Marrow"; J. Exp. Med.; May 1991; pages 1213-1225; Vol. 173; The Rockefeller University Press	
	A55	SAITTA, M. et al; "Reference Values for Immunoglobulin Kappa and Lambda Light Chains and the Kappa/Lambda Ratio in Children's Serum"; Clinical Chemistry; 1992; pages 2454-2457; Vol. 38; No. 12	
	A56	HOOD, L. et al; "Rabbit Antibody Light Chains and Gene Evolution"; Nature; December 12, 1970; pages 1040-1044; Vol. 228	
	A57	LANSORD, R; "Mechanism and Control of Immunoglobulin Gene Rearrangement"; B.D. Hames and D.M. Glover (eds); pages 1-100; IRL Press; New York; United States	
	A58	NADEL, B. et al; "Murine Lambda Gene Rearrangements: The Stochastic Model Prevails Over the Ordered Model"; The EMBO Journal; 1990; pages 435-440; Vol. 9; No. 2; Oxford University Press; United Kingdom	
	A59	ARAKAWA, H.; et al; "Re-evaluation of the Probabilities for Productive Rearrangements on the κ and λ Loci"; International Immunology; 1996; pages 91-99; Vol. 8; No. 1; Oxford University Press	

Examiner
Signature

Date
Considered

5/2/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

MAY 21 2001

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

7




of

7


Complete if Known

Application Number	09/734,613
Filing Date	December 13, 2000
First Named Inventor	BRUGGEMANN, Marianne
Group Art Unit	1651
Examiner Name	Not Yet Assigned
Attorney Docket Number	37945-0009

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A60	GIUDICELLI, V. et al; "IMGT, The International ImmunoGeneTics Database"; Nucleic Acids Research; 1997; pages 206-211; Vol. 25; No. 1; Oxford University Press	
	A81	EAGLE, H.; "Propagation in a Fluid Medium of a Human Epidermoid Carcinoma, Strain KB"; Proceedings of the Society for Experimental Biology and Medicine; 1955; pages 362-364; Vol. 89; New York	
	A82	TAUB, R. et al; "Variable Amplification of Immunoglobulin λ Light-Chain Genes in Human Populations"; Nature; July 14, 1983; pages 172-174; Vol 304; Macmillan Journals Ltd.	

Examiner
Signature



Date
Considered

8/2/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.